End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

BACKGROUND: Previous analyses from a randomised trial in women aged 24–45 years have shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN), and external genital lesions (EGLs) related to HPV 6/11/16/18. I...

詳細記述

保存先:
書誌詳細
主要な著者: Castellsagué, X, Muñoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, Luna, J, Myers, E, Mallary, S, Bautista, O M, Bryan, J, Vuocolo, S, Haupt, R M, Saah, A
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2011
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3137403/
https://ncbi.nlm.nih.gov/pubmed/21629249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.185
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料